116 related articles for article (PubMed ID: 28679024)
1. Multi-pronged proteomic analysis to study the glioma pathobiology using cerebrospinal fluid samples.
Gahoi N; Malhotra D; Moiyadi A; Varma SG; Gandhi MN; Srivastava S
Proteomics Clin Appl; 2018 May; 12(3):e1700056. PubMed ID: 28679024
[TBL] [Abstract][Full Text] [Related]
2. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
[TBL] [Abstract][Full Text] [Related]
3. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
4. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
Nakamizo S; Sasayama T; Shinohara M; Irino Y; Nishiumi S; Nishihara M; Tanaka H; Tanaka K; Mizukawa K; Itoh T; Taniguchi M; Hosoda K; Yoshida M; Kohmura E
J Neurooncol; 2013 May; 113(1):65-74. PubMed ID: 23456655
[TBL] [Abstract][Full Text] [Related]
5. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
7. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma.
Dettling S; Stamova S; Warta R; Schnölzer M; Rapp C; Rathinasamy A; Reuss D; Pocha K; Roesch S; Jungk C; Warnken U; Eckstein V; Grabe N; Schramm C; Weigand MA; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
Clin Cancer Res; 2018 Jun; 24(12):2951-2962. PubMed ID: 29563135
[No Abstract] [Full Text] [Related]
8. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
9. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
[TBL] [Abstract][Full Text] [Related]
10. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
12. Differential Proteome Profiling Analysis under Pesticide Stress by the Use of a Nano-UHPLC-MS/MS Untargeted Proteomic-Based Approach on a 3D-Developed Neurospheroid Model: Identification of Protein Interactions, Prognostic Biomarkers, and Potential Therapeutic Targets in Human IDH Mutant High-Grade Gliomas.
Louati K; Maalej A; Kolsi F; Kallel R; Gdoura Y; Borni M; Hakim LS; Zribi R; Choura S; Sayadi S; Chamkha M; Mnif B; Khemakhem Z; Boudawara TS; Boudawara MZ; Safta F
J Proteome Res; 2023 Nov; 22(11):3534-3558. PubMed ID: 37651309
[TBL] [Abstract][Full Text] [Related]
13. Autoantibody Profiling of Glioma Serum Samples to Identify Biomarkers Using Human Proteome Arrays.
Syed P; Gupta S; Choudhary S; Pandala NG; Atak A; Richharia A; K P M; Zhu H; Epari S; Noronha SB; Moiyadi A; Srivastava S
Sci Rep; 2015 Sep; 5():13895. PubMed ID: 26370624
[TBL] [Abstract][Full Text] [Related]
14. IDH mutation is paradoxically associated with higher
Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
[TBL] [Abstract][Full Text] [Related]
15. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
17. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.
Shen F; Zhang Y; Yao Y; Hua W; Zhang HS; Wu JS; Zhong P; Zhou LF
Neurosurg Rev; 2014 Jul; 37(3):367-80; discussion 380. PubMed ID: 24781189
[TBL] [Abstract][Full Text] [Related]
19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
20. Application of 2D-DIGE and iTRAQ Workflows to Analyze CSF in Gliomas.
Rao AA; Mehta K; Gahoi N; Srivastava S
Methods Mol Biol; 2019; 2044():81-110. PubMed ID: 31432408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
